UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of ~~report~~Report (Date of earliest event reported): ~~February~~March 266, 2026

~~ATAIBECKLEY~~AtaiBeckley ~~INC~~Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-43037	41-3357923
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)

c/o atai Life Sciences US, Inc.

c/o Industrious NYC

250 West 34th Street ~~New York, NY 10119(Address of principal executive offices) (Zip Code)~~

New York, NY 10119

(Address of principal executive offices) (Zip Code)

(332) 282-0507

(Registrant’s telephone number, including area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $0.01 per share	ATAI	The Nasdaq Stock Market LLC (Nasdaq Global Market)
Common stock, $0.01 par value per share	ATAI	The Nasdaq Stock Market LLC (Nasdaq Global Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging ~~growth~~Growth ~~company~~Company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 78.01. ~~Regulation~~Other ~~FD Disclosure~~Events.

OnThis ~~February~~Current 26Report on Form 8-K is being filed to provide additional information related to Beckley Psytech Limited, ~~2026~~a company incorporated in England and Wales (“Beckley Psytech”), ~~AtaiBeckley~~in connection with the previously announced share purchase agreement, dated June 2, 2025, by and among ATAI Beckley N.V., (f/k/a atai Life Sciences N.V.), a Dutch public company, Beckley Psytech and certain other parties thereto (as amended by the Side Letter Deed to the Share Purchase Agreement, dated October 23, 2025, the “~~Company~~SPA”), ~~issued~~relating ato ~~press~~ATAI ~~release~~Beckley ~~announcing~~N.V.’s ~~positive~~acquisition ~~topline~~of ~~results~~the ~~from~~entire ~~its~~issue ~~exploratory~~share ~~Phase~~capital 2aof ~~Trial~~Beckley ofPsytech not already owned by ~~EMP-01~~ ATAI Beckley N.V. (~~oral~~the ~~R-MDMA~~“Transaction”). inThe ~~Social~~Transaction ~~Anxiety~~was ~~Disorder~~consummated on November 5, 2025. ASubsequently, ~~copy~~on December 30, 2025, Atai Beckley N.V. consummated a series of transactions to change its corporate domicile from the ~~press~~Netherlands ~~release~~to isDelaware and ~~furnished~~AtaiBeckley asInc., ~~Exhibit~~a 99Delaware corporation (“AtaiBeckley”), became the successor issuer to Atai Beckley N.1V. pursuant to ~~this~~Rule ~~Current~~12g‑3(a) ~~Report~~under onthe ~~Form~~Securities ~~8-K~~Exchange Act of 1934, as amended.

AsThe ~~described~~unaudited inpro ~~the~~forma ~~press~~condensed ~~release,~~combined ~~the~~financial ~~Company~~information ~~will~~of ~~also~~AtaiBeckley ~~host~~giving aeffect ~~conference call and webcast~~ to ~~discuss~~ the ~~results~~Transaction, ofas ~~the~~well ~~EMP-01~~as ~~trial~~certain atother ~~8:00 a.m.~~related ETtransactions ondescribed ~~February 26~~therein, ~~2026.~~for ~~A copy of~~ the ~~presentation~~year toended beDecember ~~used~~31, by2025 (the ~~Company~~“Unaudited ~~during~~Pro ~~the~~Forma ~~conference~~Information”) ~~call~~are isattached ~~attched~~hereto as Exhibit 99.21 toand ~~this~~incorporated ~~Current~~herein ~~Report~~by onreference. The Unaudited Pro Forma Information included in this Form 8-K is presented for illustrative purposes only and is ~~incorporated~~not ~~herein~~necessarily byindicative ~~reference~~of what AtaiBeckley’s actual results of operations would have been had such transactions been completed on the dates indicated.

The information furnished under this Item 7.01, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or the Exchange Act, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing..

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1*		Press Release of AtaiBeckley Inc., dated February 26, 2026.
99.1		Unaudited pro forma condensed combined financial information of AtaiBeckley giving effect to the Transaction, as well as certain other related transactions described therein, for the year ended December 31, 2025.
99.2*		Presentation of AtaiBeckley Inc., dated February 26, 2026
104		Cover Page Interactive Data File (embedded within the inline XBRL document).
*		Furnished herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ATAIBECKLEY INC.
Date: February 26, 2026	By:	/s/ Srinivas Rao
Date: March 6, 2026	By:	/s/ Srinivas Rao
	Name:	Srinivas Rao
	Title:	Chief Executive Officer

Filing Compare · AtaiBeckley Inc.